TUESDAY, Nov. 12, 2024 (HealthDay News) -- For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

"Canagliflozin was linked to enhanced iron utilization and elevated hemoglobin levels in adults with type 2 diabetes and ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

About half of all people with chronic heart failure have this type. Empagliflozin belongs to a class of medicines called SGLT2 inhibitors. Evidence demonstrates that SGLT2 inhibitors can ease the ...

A recent study has shown that the weight-loss drug Ozempic, along with other medications in its class, may significantly ...

The researchers revealed that GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes medications like Jardiance or Farxiga ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...